Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Launch of 20 new medicines expected by 2030
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
Additional data from APPRAISE ATP trial reinforce modular therapy approach
The collaboration aims to bolster healthcare entrepreneurship
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subscribe To Our Newsletter & Stay Updated